Advances in treatment of inoperable NSCLC: gemcitabine doublets--a promising alternative.
Oncology (Williston Park)
; 14(7 Suppl 4): 7-14, 2000 Jul.
Article
in En
| MEDLINE
| ID: mdl-10960939
ABSTRACT
Gemcitabine (Gemzar) was originally approved for use in combination with cisplatin (Platinol) for the treatment of advanced non-small-cell lung cancer (NSCLC). Research began to focus on combining gemcitabine with newer drugs, such as carboplatin (Paraplatin), vinorelbine (Navelbine), the taxanes, and the camptothecins, when it became clear that these agents had potentially increased efficacy and fewer side effects than the standard treatment. This article will briefly review the original experience with the gemcitabine/cisplatin doublet and then examine the experience to date with non-cisplatin-based gemcitabine doublet combinations in the treatment of advanced NSCLC.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antineoplastic Combined Chemotherapy Protocols
/
Carcinoma, Non-Small-Cell Lung
/
Taxoids
/
Deoxycytidine
/
Lung Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Oncology (Williston Park)
Journal subject:
NEOPLASIAS
Year:
2000
Document type:
Article
Affiliation country: